bcl-2 protein has been detected in surgical specimens and cultured permanent cell lines of non-Hodgkin's lymphomas and leukemias using enzyme immunohistochemistry and immunofluorescence with anti-bcl-2 monoclonal antibodies. Of 40 surgical specimens, bcl-2 protein was expressed in 50% of B-cell and 41% of T-cell lymphomas, both with and without the bcl-2 gene rearrangement. In investigations of 38 hematopoietic cell lines, bcl-2 protein was detected not only in lymphoid cell lines but also in myeloid cell lines. In situ hybridization and immunohistochemical analysis of reactive HE bcl-2 GENE, which is located closely to or within T the breakpoint of chromosome 18, was cloned as a proto-oncogene from a follicular lymphoma cell line that carried the t(14;18) chromosomal transl~cation.l-~ The role of bcl-2 protein in lymphomagenesis still remains unsolved. Recently, Hockenbery et aI4 have reported that bcl-2 protein is an inner mitochondrial membrane protein that blocks programmed cell death. In analyses using transgenic murine models, Strasser et aI5 and McDonnell and Korsmeye+ reported that lymphoid tumors were induced under the cooperation of the c-myc gene and the bcl-2 gene.
lymph nodes showed that lymphocytes in mantle zones and paracortical areas expressed bcl-2 protein consistent with the messenger RNA distribution and that germinal center cells showed abundant bcl-2 transcript, despite the absence of detectable bcl-2 protein. These results suggest that bcl-2 protein is broadly expressed in various hematopoietic neoplasms not restricted in t(14;18) lymphomas and that germinal center cells may be involved in some arrest of bcl-2 protein expression at the posttranscriptional level.
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bcl-2 protein in vitro, but the mechanism of bcl-2 gene regulation in germinal center cells in vivo still remains unknown.
In this study, we describe the expression of bcl-2 protein and bcl-2 mRNA in non-Hodgkin's lymphomas (NHLs) and in normal lymphoid tissues to clarify a mechanism of bcl-2 gene regulation.
MATERIALS AND METHODS
Tissue samples were obtained surgically from patients with NHLs or reactive lymphoid hyperplasias, and were examined histologically and immunophenotypically. Most of these tissues were also analyzed immunogenotypically using Southern blot hybridization of the IgH joining segment (JH) and T-cell receptor (TCR) p-chain genes. Histologically, the neoplastic samples were classified according to the Working Formulation classification" and the updated Kiel cla~sification.~~J~ Primary gastrointestinal (GI) lymphoma was defined as a lymphoma localized within the GI tract without lymphnodal involvement on the first diagnosis.
Thirty-eight cultured hematopoietic cell lines derived from lymphomalleukemias were studied (see Tables 5 and 6 ). All cell lines studied had already been cytologically examined for their phenotypes and categorized into a particular differentiation stage according to a model proposed by Minowada for the proliferation and differentiation of leukemiallymphoma cell lines.*O Anti-bcl-2 a protein mouse monoclonal antibodies (MoAbs), Bcl-2 100a and 124a, were used for the immunohistochemical analysis of bcl-2 protein, which can specifically recognize the 26-Kd bcl-2 gene product, bcl-2 a protein.I4 For enzyme immunohistochemistry, frozen specimens from lymphoma tissues fixed in acetone were stained using the avidinbiotin-peroxidase complex (ABC) method. Briefly, frozen specimens were incubated for 1 hour with 20-fold diluted anti-bcl-2 MoAb at room temperature. After washing three times with phosphate-buffered saline (PBS) containing 0.1% Tween 20, they were incubated with biotinylated goat antimouse Ig for 30 minutes at room temperature. After further washings, ABC solution (Immu-Mark; ICN Biomedicals, Inc, Costa Mesa, CA) was then added and incubation continued for 30 minutes at room temperature. The specimens were developed in diaminobenzidine solution to detect peroxidase activity. The results of the immunohistochemical staining were evaluated only as positive or negative to exclude subjectivity and to take different fixation conditions into consideration. As for tissue samples examined in the current study, immunophenotypic analyses were performed by the immunoperoxidase method using a panel of MoAbs and by Southern blot hybridization using JH probe and TCRP-chain gene (Jp2) probe. MoAbs used in immunoperoxidase method were as follows: antiLeu-4 (CD3), anti-Leu-3a (CD4), anti-Leu-2a (CDB), antiTissue samples.
Cell lines.
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Leu-12 (CD19), anti-Leu-16 (CD20), and anti-Leu-14 (CD22) (Becton Dickinson, Mountain View, CA).
Immunofluorescence. For indirect immunofluorescence, frozen lymphoma tissue specimens and cytosmears of cultured cell lines were stained with Bcl-2 100a MoAb at a dilution of 1:40 for 30 minutes at room temperature. As the second antibody, fluorescein isothiocyanate (F1TC)-conjugated antimouse Ig goat F(ab')z (Tago, Inc, Burlingame, CA) was used at a dilution of 1:20. For double immunostaining, the specimens were first stained with anti-bcl-2 MoAb using FITC-conjugated second antibody and then with phycoerythrin (PE)-conjugated OKT3 (Ortho Diagnostic Systems, Inc, Raritan, NJ).
Cell lines stained with Bcl-2 1OOu MoAb using immunofluorescence were analyzed by flow cytometry (Epics 753; Coulter Corp, Hialeah, FL). After blocking by incubating with normal goat serum for 15 minutes, lo6 cells from each cell line were incubated with 20-fold diluted anti-Bcl-2 MoAb (Bcl-2 1OOu) at room temperature for 30 minutes. Then, after washing three times with PBS containing 0.1% Tween 20, they were incubated with 20-fold diluted FITC-conjugated goat antimouse IgG (Becton Dickinson) at room temperature for 30 minutes. After washing three times again with PBS, they were sequentially analyzed by a flow cytometer. The positive percentage of each cell line was calculated by subtracting the integral value of background staining found when only the FITC-conjugated second antibody was used from that of the Bcl-2 staining. Some cell lines were also stained with CD3, CD4, CD19, and CD20 to confirm their immunophenotypes.
High molecular weight genomic DNA was extracted from fresh lymph node tissues of patients with NHL or non-neoplastic disease, and used for detection of gene rearrangements according to the method described by Southern.21 The probes used were pFL-1 for the bcl-2 gene major breakpoint region (mbr) and pFL-2 for the bcl-2 gene minor cluster region (mcr), both of which were kindly provided by Dr M.L. Cleary (Stanford University Medical School, Stanford, CA).2,3 The JH gene was provided by Dr T. Honjo (Kyoto University, Kyoto, Japan, through the Japanese Cancer Research Resources Bank). The TCRP-chain genes, JP2 and Cpl, were provided by Dr J. Sklar (Stanford University Medical School). The Ig light chain constant region CK and Ch genes were provided by Dr P. Leder (Harvard Medical School, Boston, MA).
In situ hybridization was performed on tissue specimens and cytosmears of cell lines to detect mRNA from the bcl-2 gene. Tissues, which were surgically obtained, were fixed in RNase-free 4% paraformaldehyde solution overnight, sequentially dehydrated with 70%, 80%, 90%, and 100% ethanol, embedded in paraffin, and were cut at 4.5-pm thickness. Cultured cells Flow cytometric analysis.
Southem blot hybridization.
In situ hybridization. were cytosmeared on glass slides coated with 3-(triethoxysilyl)-propylamin (Merck, Darmstadt, Germany) and fixed with RNasefree 4% paraformaldehyde. Deparaffined tissue specimens and cytosmears were incubated in Tris-HC1 containing 0.01% proteinase K (Sigma, St Louis, MO) for appropriate time and acetylated with 0.1 mol/L triethanolamine containing 0.2% acetic acid for 15 minutes. After sequential dehydration in alcohol solutions, each specimen was hybridized with a digoxygenin (Dig)-labeled antisense RNA probe that was synthesized from bcl-2 mbr c-DNA (pFL-1) as a template using an in vitro transcription kit (Boehringer Mannheim, Mannheim, Germany). After two washings with 0 . 2~ SSC containing 0.1% sodium dodecyl sulfate (SDS), the specimens were incubated in alkaline phosphatase-conjugated anti-Dig antibody (Boehringer Mannheim) for 30 minutes. They were washed several times, developed by adding the substrate for alkaline phosphatase, and then counterstained with methylgreen. As a control for the antisense bcl-2 RNA probe, the sense sequence RNA probe was synthesized and used for hybridization at the same concentration and in the same way. Total RNA was extracted from the 4 cell lines (SU-DHL-4, BALM-1, SCOTT, and JURKAT) and further purified into poly(A)+ RNA with oligo (dT) latex (Takara Co, Ltd, Tokyo, Japan). Approximately 1.5 pg of poly(A)+ RNA from each cell line purified with oligo (dT) latex was fractionated in Northem blot hybridization. Table 1 . The nylon filter was hybridized with a 32P-labeled antisense RNA probe against the mRNA of the bcl-2 gene (approximately lo6 cpm/mL of hybridization buffer) at 50°C for 12 hours, washed twice with 2 x SSC/O.l% SDS at room temperature for 30 minutes, immersed in an RNase solution (10 mmol/L Tris-HC1, 500 mmol/L NaCI, 1 mmol/L EDTA, and 10 kg/mL RNase), and then incubated at 37°C for 15 minutes. The filter was then washed twice with 0.2X SSC/O.l% SDS at 65°C for 15 minutes and subsequently autoradiographed for about 48 hours. The RNA probe labeled with 32P by random hexanucleotide priming was prepared by in vitro transcription using pFL-1 probe as the bcl-2 cDNA template that was cloned into Blue Script KS M13(-) (Stratagene, San Diego, CA).
Thirteen cell lines were selected, taking their immunophenotypes and differentiation stages into consideration. Each cell line (5 X lo7 cells) was harvested and lysed on ice for 15 minutes with 0.5 mL of an extraction buffer containing 0.5% Nonidet P-40 (NP-40), 50 mmol/L Tris (pH 7.2), 0.15 mol/L NaCI, 2 mmol/L EDTA, 10 mmol/L iodoacetoamide, 0.02% NaN3, and 1 mmol/L phenylmethylsulfonyl fluoride. After centrifugation at 20,OOOg for 20 minutes at 4"C, the supernatants were collected and mixed with SDS sample buffer with or without 2-mercaptoethanol.
The concentration of extracted protein was determined according to the method of Bradford.23 The samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the proteins on the gels were electroblotted onto nitrocellulose membranes in transfer buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and 20% methanol. After the transfer of proteins, the membrane was treated with Block Ace (Dainippon Pharmaceutical Co, Ltd, Osaka, Japan) for 30 minutes to block nonspecific binding and then incubated with either anti-bcl-2 MoAb (Bcl-2 1OOru) or a mouse myeloma protein, MOPC-21 (Sigma), which was used as a negative control antibody, for 1 hour at room temperature. The membrane strips were washed with a washing buffer containing 0.1% Tween 20 in 10% Block Ace solution. The antibodies bound to the nitrocellulose membrane were visualized by using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) that detects mouse IgG with a biotin-conjugated horse antibody and an horseradish peroxidase-conjugated avidin. The stain was developed with a substrate solution containing 0.01% H202 and 0.5 mg/mL 4-chloro-1-naphtol.
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RESULTS
The results of the bcl-2 gene rearrangement analysis and the expression of the bcl-2 gene product in follicular lymphomas of lymph nodes are summarized in Table 1 . Comigrating rearrangements of the mbr locus of the bcl-2 gene with the JH locus were found in four of eight cases of follicular lymphoma, while expression of bel-2 protein was found in seven of eight cases (88%). In nodal diffuse B-cell lymphomas, one of nine cases (case 13) showed rearrangement of the bel-2 gene, while bel-2 protein was detected in two cases with no rearrangement of the bel-2 gene (Table 2 ). There was no essential difference between Bcl-2 l O O a MoAb and Bcl-2 124a MoAb in their immunohistochemical staining patterns. In the analysis of B-cell lymphomas of the GI tract (Table 3) , only 1 of 11 cases (case 21) showed comigrating rearrangements of the bel-2 mcr locus with the JH segment, while 5 of 11 cases, including case 21, were diffusely positive for bel-2 protein (Fig 1A) . bcl-2 protein was also detected in 5 of 12 cases of Tissue samples. T-cell lymphoma (Table 4) . Histologically, tumor cells expressed bel-2 protein diffusely and strongly. Among them, one case of T-cell lymphoblastic lymphoma (case 29; CD1+, CD3+, CD4+, CD8+; data not shown) was examined by in situ hybridization. In this case, the signal was diffusely detected in most of the tumor cells with a cytoplasmic staining pattern (Fig lC) , which was consistent with bcl-2 protein expression (Fig 1B) . In all six cases of reactive lymph node hyperplasia, non-neoplastic lymphocytes in the mantle zone and the interfollicular area were diffusely positive for bcl-2 protein, but germinal centers were almost negative, except for a few scattered positive cells (Fig 1D) . After further analysis using immunofluorescence with PEconjugated CD3 MoAb and FITC-conjugated Bcl-2 10001, we confirmed the expression of bcl-2 protein on reactive T lymphocytes (Fig 1E) . In the germinal centers, a few lymphocytes expressed only bcl-2 protein or CD3. In addition, in situ hybridization showed the histologic distribution of bcl-2 mRNA in reactive lymph node hyperplasia. bcl-2 mRNA was much more strongly expressed on most of the follicular center cells in the germinal centers that were immunohistochemically negative for bcl-2 protein in comparison with mantle zone lymphocytes (Fig 1F and G) . Approximately 50% of the mantle zone B lymphocytes and of T-zone lymphocytes also expressed bcl-2 mRNA in a diffuse scattered pattern, which was consistent with the localization of bcl-2 protein in the immunohistochemical analyses. Thirty-eight hematopoietic cell lines were investigated for the expression of bcl-2 protein by immunofluorescence with Bcl-2 10001. Two lymphoid precursor cell lines, REH and NALL-1 (non-T, non-B acute lymphocytic leukemia cells), were strongly positive for bcl-2 protein.
Cell lines.
Eleven of 17 B-cell lines (65%) were positive for bcl-2 protein, which broadly included cells from the pre-B-cell group to the mature B-cell (myeloma cell) group (Table 5 ). In the investigation of T-cell leukemia/lymphoma cell lines, 9 of 17 (53%) lines were also positive for bcl-2 protein (Table 6 ). To clarify a correlation between bcl-2 gene rearrangement and bel-2 protein expression, detailed investigations were performed for the selected cell lines, SU-DHL-4, BALM-1, SCOTT, and JURKAT. Both SU-DHL-4, which showed comigrating rearrangements of bcl-2 locus with the JH locus, and SCOTT without the bcl-2 gene rearrangement were strongly positive for bcl-2 protein by immunofluorescence (Fig 1H and I) . In addition to these findings, JURKAT, which belongs to a T-cell lymphoma of intrathymic differentiation stage, was also positive for bcl-2 protein (data not shown). Interestingly, BALM-1, which showed comigrating rearrangements of the bcl-2 gene with the JH locus, was stained quite weakly and in a small number. Flow cytometry showed that most of the SU-DHL-4, SCOTT, and approximately 70% of the JURKAT cells expressed bcl-2 protein. Again, in BALM-1, its expression was less than 5% (Fig 2) . Using in situ hybridization, we confirmed that bcl-2 mRNA was expressed on all four cell lines (Fig 1J) . At the same time, the expression of bcl-2 mRNA was detected from the poly(A)+ RNA of all four cell lines by Northern blot hybridization (Fig 3) . The intensity of the signal was stronger in the three B-cell lines than in the T-cell line, JURKAT. SU-DHL-4 and BALM-1 nomu.4-expressed abnormal transcripts that derived from the recombination of the bcl-2 gene with the JH locus. SCOTT and JURKAT, which lack the t( 14;lS) chromosomal translocation, displayed a 6.0-kb normal transcript of bcl-2 mRNA, and the cxpression level of mRNA in S C O T was almost the same as that in SU-DHL-4 and BALM-1. Westem blotting also showed bcl-2 protein in all 13 hematopoietic cell lines examined (Fig 4) . Not only SU-DHL-4, BALM-1, and Boar 88, which showed the bcl-2 gene rearrangement, but also both T-cell and B-cell leukemias and lymphomas without the rearrangement expressed the same single band of approximately 26 Kd, which corresponds to the molecular wcight of bcl-2 protein. In B-cell lines, there seems to be a similar level of the bcl-2 protein expression between the translocated SU-DHL-4 and the nontranslocated SCOTT.
Even within the translocated B-cell lines, such as SU-DHL-4, Boar SS, and BALM-1, the expression level varies remarkably from one to another. In neoplastic diseases, 88% of follicular lymphomas of lymph nodes expressed bcl-2 protein. Diffuse B-cell lymphomas from lymph nodes showed a lower percent of product expression (22%), and GI tract B-cell lymphomas showed moderate bcl-2 product expression (50%). Concerning the correlation of bcl-2 protein and bcl-2 rearrangement, 57% of the follicular lymphomas that were positive for bcl-2 protein showed comigrating rearrangements of the bcl-2 gene with the JH locus, and one of seven positive cases (14%) of diffuse lymphomas showed bcl-2 rearrangement (Tables 1 through 3) . One diffuse large cell lymphoma (case 13) had comigrating rearrangements of the bcl-2 gene and JH locus, but tumor cells displayed no detectable bcl-2 protein. The t( 14;18) translocation usually results in deregulated expression of the bcl-2-Zg fugion gene. In case 13, a posttranscriptional process may be suppressed by an unknown mechanism or, alternatively, bcl-2 protein could not 8-blast I n SKW4(+) \ be detected by the poor fixation condition. We also detected bcl-2 protein in 41% of T-cell lymphomas with no rearrangement of the bcl-2 gene. These results are consistent with other rep0rts.~~J5 bcl-2 protein was expressed in many hematopoietic cell lines. The cell lines examined were assigned to each differentiation stage according to a proposed model scheme for human hematopoietic cell differentiation and correlated with expression of bcl-2 protein (Fig 5) . There seems to be no significant relationship between bcl-2 expression and differentiation stages of lymphoid cell lines. The results contradict some previous reports that bcl-2 expression was differentiation associated.lOP The bcl-2 gene was shown to be downregulated at later stages of B-cell differentiation, but our study clearly showed bcl-2 expression in myeloma cell lines, consistent with another report.26 This discrepancy could possibly be explained by methodologic differences or sample differences between humans and murines. Detailed analyses were performed on four representative hematopoietic cell lines, SU-DHL-4, SCOTT, BALM-1, and JUR-KAT. In Northern blot hybridization, we detected the 6.0-kb normal transcript of the bcl-2 gene in both SCOTT and JURKAT, without evidence of the t( 14;18) translocation. In nontranslocated lymphoma cells and normal lymphocytes, mechanisms other than t(14;18) translocation, including somatic mutation, may deregulate bcl-2 expression. Although BALM-1 cells expressed a quite low level of bcl-2 protein, they produced mRNA at a level comparable with other B-cell lines. This phenomenon indicates that expression of bcl-2 protein is also regulated at the posttranscriptional level, as was supposed in germinal center lymphocytes. Furthermore, bcl-2 expression was not restricted to the lymphoid lineage and was also shown in myeloid cell lines, as reported. 27 From the findings mentioned above, bcl-2 protein, although its expression level varies somewhat quantitatively, is broadly expressed in hematopoietic neoplasms irrespective of the bcl-2 gene rearrangement. In neoplastic lymphoid cells, this product may contribute to preneoplastic For personal use only. on October 25, 2017. by guest www.bloodjournal.org From
